The University of Hong Kong (HKU) announced Wednesday that its nasal spray vaccine opposed to coronavirus had received regulatory approval for human clinical trials, according to the ECNS news firm’s report.
The nasal spray vaccine is the first of its kind to have obtained approval from the Chinese National Medical Products Administration.
HKU said in a statement that its vaccine strategy had been decided as one of five vaccine technologies through the Ministry of Science and Technology for additional evaluation.
China, a pioneer of the possible coronavirus vaccine after AstraZeneca had to temporarily stop its vaccine trials.
Meanwhile, China National Biotec Group Co stated that neither recipient of its two coronavirus vaccines had reported any adverse reactions or infections.
Recently, Brazil also announced that 3 clinical trials in the country for the vaccine developed through China have shown promising results.
The Brazilian Health Administration expects the vaccine to be available until the end of 2020, Aljazeera reported.
Already have an account? Connect
Start your 14 day loose trial. Sign up
Get full virtual playback of The Hindu BusinessLine, The Hindu, Frontline, Sportstar, Crossword, Epaper from The Hindu and The Hindu BusinessLine at A SINGLE REDUCED PRICE.
Get a diverse set of perspectives from our experts in portfolio, banking, economics, environment and more.
Access Hindu Businessline content on desktops, tablets, and mobile devices.
Discover an ad-free cleaner with faster charging times.
Customize your personal tastes and get personalized advice on your interest.
greater